{"id":"W2995123342","doi":"10.1016/j.jtho.2019.12.107","title":"PD-L1 Testing for Lung Cancer in 2019: Perspective From the IASLC Pathology Committee","year":2019,"lang":"en","type":"review","venue":"Journal of Thoracic Oncology","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":345,"is_retracted":false,"has_abstract":false,"ca_institutions":"Sunnybrook Health Science Centre; Health Sciences Centre; University Health Network; Princess Margaret Cancer Centre","funders":"Merck Sharp and Dohme; Genentech; Takeda Pharmaceuticals U.S.A.; Meso Scale Diagnostics; AbbVie; Chugai Pharmaceutical; Roche; EMD Serono; Novartis; MedImmune; Agilent Technologies; GlaxoSmithKline; Merck; Bayer; Bayer Corporation; Bristol-Myers Squibb; AstraZeneca; Boehringer Ingelheim; Amgen; Pfizer","keywords":"Medicine; Companion diagnostic; Lung cancer; Immunohistochemistry; Oncology; Cancer; Clinical trial; Pathology; Internal medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004177046,0.0006978073,0.001831532,0.00226239,0.0002953232,0.001655121,0.001489553,0.002245485,0.003121339],"category_scores_gemma":[0.007299422,0.0003326027,0.001248919,0.001745162,0.0005840481,0.001967396,0.001002669,0.003897837,0.001645028],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001884154,"about_ca_system_score_gemma":0.00447389,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00344657,"about_ca_topic_score_gemma":0.008382047,"domain_scores_codex":[0.9989671,0.0002849268,0.0001917309,0.0001625346,0.0002923105,0.0001014382],"domain_scores_gemma":[0.9938531,0.002768707,0.0005882479,0.00009155557,0.002338598,0.0003598155],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001339119,0.00002861512,0.0008414481,0.01020779,0.0001979955,0.00009901902,0.00002410933,0.000319479,0.0002777216,0.003383535,0.1422983,0.8421881],"study_design_scores_gemma":[0.00007036313,0.0001171598,0.002284542,0.0241776,0.0003998156,0.0007604756,0.00006090304,0.0001770362,0.0001927105,0.002270492,0.969455,0.0000339208],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.00006811196,0.990432,0.000102722,0.007193756,0.001134549,0.000005076403,0.00009357789,0.000008025952,0.0009621618],"genre_scores_gemma":[0.001431621,0.9892637,0.0003335337,0.006715989,0.001604919,0.00001436098,0.0001801905,0.000004286044,0.0004513335],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.004177046,"threshold_uncertainty_score":0.02209061,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08695334608872189,"score_gpt":0.500247038117566,"score_spread":0.4132936920288441,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}